John Jesitus is a medical writer based in Westminster, CO.

Articles

A vast majority of patients with atopic dermatitis (AD) are satisfied with dupilumab (Dupixent, Sanofi and Regeneron) treatment, according to research presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress.

AD patients reflect high satisfaction, safety with dupilumab

A new innovative report identifies gaps and offers solutions for improving quality of care in atopic dermatitis (AD).

Identifying and improving quality of care in AD

New study data shows that in adults with atopic dermatitis, dupilumab has performed as expected, with continued efficacy and no new safety signals. 

Three-year eczema data show sustained safety, efficacy

Infants with eczema may require different approaches to preventing food allergies, including early introduction of peanuts to increase oral exposure to allergens before skin exposure.

Infant eczema impacts food allergy plan 

Dupilumab and JAK inhibitors are leading the way in atopic dermatitis treatment, but there are numerous clinical trials of both new biologics and new small molecule drugs, and future treatment regimens likely will utilize both. 

Biologics, small molecule drugs expand AD options 

The first and only atopic dermatitis conference, Revolutionizing Atopic Dermatitis (RAD), will be hosting its third event, in a virtual format.

Revolutionizing Atopic Dermatitis conference to return for third event

In a recent phase 3 trial, dupilumab (Dupixent, Sanofi and Regeneron) demonstrated positive results in itch reduction, skin clearance and quality-of-life. Indicating the biologic as a viable treatment option for severe atopic dermatitis in younger children.  

Dupilumab provides option for severe AD in younger children 

A recent review reveals older adults are underrepresented in trials investigating systemic immunomodulators as a treatment for atopic dermatitis. 

Older adults underrepresented in atopic dermatitis research  

Adults with atopic dermatitis (AD) stay on dupilumab (Dupixent, Sanofi and Regeneron) significantly longer than on cyclosporine, according to a recent study. 

Dupilumab outlasts cyclosporine 

Across all doses, lebrikizumab showed significant dose-dependent improvement in primary study endpoints for improvements in atopic dermatitis, according to data from phase 2b trials.